Coronavirus Vaccine Development: Immunological Responses, Adjuvants, and Precision Vaccinology Strategies
Overview
This paper examines the development of effective coronavirus vaccines in response to global pandemic concerns. It discusses vulnerability in elderly populations with preexisting conditions, the role of spike protein antigens, and the use of adjuvants combined with precision vaccinology to enhance immune responses in immunocompromised individuals.
What this essay covers
- Introduction and pandemic context highlighting increased infection rates and WHO involvement
- Vulnerability of elderly populations and immunocompromised individuals to COVID-19
- Coronavirus spike protein as vaccine antigen and immune system recognition mechanisms
- Adjuvants as immune response enhancers and precision vaccinology screening approaches
Preview
Corona Virus Vaccine
Name
Institution Affiliation
Corona Virus Vaccine
An increase in the number of Coronavirus infections every day globally necessitates the development of an effective and able vaccine to eliminate the virus. In response to the health sector crisis, researchers are in the limelight to search for a vaccine that will stop the Coronavirus. Nations worldwide are doing their best to eliminate the pandemic that has taken the world by storm. On the other hand, the World Health Organization (WHO) is at the frontline with measures being put in place to ensure the pandemic has been defeated. Therefore, it is worth noting that research on the Coronavirus is at its peak, as the article investigates.
Research for the Coronavirus causing organisms are on the increase, more so targeting the older generation. The older generation is put at risk because it is prone to other ailments that come with age, like blood pressure and diabetes (Khamsi, 2020). Moreover, some people are at the most significant risk of developing Coronavirus due to acute respiratory syndrome-2 (SARS-CoV-2).
The World Health Organization (WHO) says that older people and those who have preexisting ailments are the most vulnerable to COVID-19. Ofer Levy, a Harvard Medical School professor, says that older people have a different immune system than healthy adults in their middle years (Paguio et al., 2020). Levy adds that because of the older adults' weak immune system, they cannot respond to immunization. Therefore there cannot be a single vaccine that would fit every individual.